

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)



(10) International Publication Number
WO 2023/285560 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2022/069659

Published:

(22) International Filing Date:
13 July 2022 (13.07.2022)

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2021/069869
15 July 2021 (15.07.2021) EP

(71) Applicant: **BIONTECH SE** [DE/DE]; An der Goldgrube
12, 55131 Mainz (DE).

(72) Inventors: **SAHIN, Ugur**; c/o BioNTech SE, An der Gold-
grube 12, 55131 Mainz (DE). **STADLER, Christiane**; c/
o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE).
LINDEMANN, Claudia; c/o BioNTech SE, An der Gold-
grube 12, 55131 Mainz (DE). **ELLINGHAUS, Ursula**;
c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz
(DE). **BÄHR-MAHMUD, Hayat**; c/o BioNTech SE, An
der Goldgrube 12, 55131 Mainz (DE). **FISCHER, Leyla**; c/
o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE).
CHATURVEDI, Anuhar; c/o BioNTech SE, An der Gold-
grube 12, 55131 Mainz (DE).

(74) Agent: **SCHNAPPAUF, Georg**; Zwicker Schnappauf &
Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 Mün-
nich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: AGENTS ENCODING CLDN6 AND CD3 BINDING ELEMENTS FOR TREATING CLDN6-POSITIVE CANCERS

(57) Abstract: The present invention generally relates to binding agents that are at least bispecific for the binding to CD3 and CLDN6, i.e., they are capable of binding to at least CD3 and CLDN6. Specifically, the present invention relates to RNA encoding these binding agents which may be used in the treatment or prevention of cancer in a subject.

WO 2023/285560 A1